Earlier this week, drugmaker Sanofi (NYSE:SNY) won approval for its multiple sclerosis treatment Lemtrada in the European Union. While the drug has yet to get the green light in the U.S., it is a key addition to Sanofi's multiple sclerosis lineup, which also includes the oral medication Aubagio. But can the company compete with Biogen (NASDAQ:BIIB) and its recently launched MS medication Tecfidera? Analysts David Williamson and Max Macaluso discuss this market in the following video.
Editor's note: At 6:36, the speaker incorrectly states that Sanofi had a partnership with Rigel Pharmaceuticals. The Fool regrets the error.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
This Is Why Alnylam Pharmaceuticals Soared 249% in 2017
It was a breakout year for the clinical-stage biotech.
3 Top Value Stocks to Buy in 2018
Express Scripts Holding Company, Horizon Pharma plc, and Sanofi plc are three cheap stocks worth considering in 2018.
3 High-Yield Dividend Stocks to Buy in 2018
These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.